Los Angeles Capital Management LLC Acquires 74,360 Shares of DexCom, Inc. (NASDAQ:DXCM)

Los Angeles Capital Management LLC increased its holdings in DexCom, Inc. (NASDAQ:DXCM) by 1,104.7% in the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 81,091 shares of the medical device company’s stock after buying an additional 74,360 shares during the quarter. Los Angeles Capital Management LLC’s holdings in DexCom were worth $6,306,000 at the end of the most recent reporting period.

A number of other hedge funds have also bought and sold shares of DXCM. Versant Capital Management Inc bought a new stake in shares of DexCom in the fourth quarter worth approximately $25,000. Heck Capital Advisors LLC bought a new position in DexCom during the fourth quarter valued at approximately $38,000. Midwest Capital Advisors LLC purchased a new stake in DexCom in the fourth quarter worth approximately $54,000. Rothschild Investment LLC grew its position in DexCom by 250.5% in the 4th quarter. Rothschild Investment LLC now owns 750 shares of the medical device company’s stock worth $58,000 after purchasing an additional 536 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its stake in DexCom by 46.7% during the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 833 shares of the medical device company’s stock valued at $65,000 after buying an additional 265 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently issued reports on DXCM. Canaccord Genuity Group raised their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Morgan Stanley raised their target price on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Wells Fargo & Company boosted their price target on DexCom from $90.00 to $94.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and increased their price objective for the stock from $86.00 to $104.00 in a research note on Thursday, January 16th. Finally, StockNews.com lowered shares of DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $99.06.

Insider Buying and Selling

In other DexCom news, COO Jacob Steven Leach sold 2,634 shares of the business’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $228,920.94. Following the sale, the chief operating officer now owns 268,644 shares in the company, valued at $23,347,850.04. The trade was a 0.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $2,899,230.69. Following the transaction, the chief executive officer now owns 319,037 shares of the company’s stock, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is owned by insiders.

DexCom Stock Performance

NASDAQ DXCM opened at $89.91 on Thursday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a twelve month low of $62.34 and a twelve month high of $142.00. The business has a 50-day moving average price of $84.29 and a 200-day moving average price of $76.47. The firm has a market cap of $35.13 billion, a price-to-earnings ratio of 62.87, a price-to-earnings-growth ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. As a group, equities research analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.